Key Points Net loss attributable to common stockholders totaled $20.7 million for the three months ended June 30, 2025. Net loss attributable to common stockholders was $20.7 million for the three ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

Supergut, a leader in gut-health innovation, announced the launch of three new flavors of its GLP-1 Booster: Blood Orange, ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...